IFN	B-GP
-	I-GP
γ	I-GP
Stimulates	O
Autophagy	O
-	O
Mediated	O
Clearance	O
of	O
Burkholderia	B-OG
cenocepacia	I-OG
in	O
Human	B-OG
Cystic	B-DS
Fibrosis	I-DS
Macrophages	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
KA	O
AOA	O
BTK	O
.	O

Performed	O
the	O
experiments	O
:	O
KA	O
MFT	O
BTK	O
.	O

Analyzed	O
the	O
data	O
:	O
KA	O
MFT	O
AOA	O
BTK	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
AOA	O
BTK	O
.	O

Wrote	O
the	O
paper	O
:	O
KA	O
BTK	O
.	O

Burkholderia	B-OG
cenocepacia	I-OG
is	O
a	O
virulent	O
pathogen	O
that	O
causes	O
significant	O
morbidity	O
and	O
mortality	O
in	O
patients	O
with	O
cystic	B-DS
fibrosis	I-DS
(	O
CF	B-DS
),	O
survives	O
intracellularly	O
in	O
macrophages	O
,	O
and	O
uniquely	O
causes	O
systemic	B-DS
infections	I-DS
in	O
CF	B-DS
.	O

Autophagy	O
is	O
a	O
physiologic	O
process	O
that	O
involves	O
engulfing	O
non	O
-	O
functional	O
organelles	O
and	O
proteins	O
and	O
delivering	O
them	O
for	O
lysosomal	O
degradation	O
,	O
but	O
also	O
plays	O
a	O
role	O
in	O
eliminating	O
intracellular	O
pathogens	O
,	O
including	O
B	B-OG
.	I-OG
cenocepacia	I-OG
.	O

Autophagy	O
is	O
defective	O
in	O
CF	B-DS
but	O
can	O
be	O
stimulated	O
in	O
murine	O
CF	B-DS
models	O
leading	O
to	O
increased	O
clearance	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
,	O
but	O
little	O
is	O
known	O
about	O
autophagy	O
stimulation	O
in	O
human	B-OG
CF	B-DS
macrophages	O
.	O

IFN	B-GP
-	I-GP
γ	I-GP
activates	O
macrophages	O
and	O
increases	O
antigen	O
presentation	O
while	O
also	O
inducing	O
autophagy	O
in	O
macrophages	O
.	O

We	O
therefore	O
,	O
hypothesized	O
that	O
treatment	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
would	O
increase	O
autophagy	O
and	O
macrophage	O
activation	O
in	O
patients	O
with	O
CF	B-DS
.	O

Peripheral	O
blood	O
monocyte	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
were	O
obtained	O
from	O
CF	B-DS
and	O
non	O
-	O
CF	B-DS
donors	O
and	O
subsequently	O
infected	O
with	O
B	B-OG
.	I-OG
cenocepacia	I-OG
.	O

Basal	O
serum	O
levels	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
were	O
similar	O
between	O
CF	B-DS
and	O
non	O
-	O
CF	B-DS
patients	O
,	O
however	O
after	O
B	B-DS
.	I-DS
cenocepacia	I-DS
infection	I-DS
there	O
is	O
deficient	O
IFN	B-GP
-	I-GP
γ	I-GP
production	O
in	O
CF	B-DS
MDMs	O
.	O

IFN	B-GP
-	I-GP
γ	I-GP
treated	O
CF	B-DS
MDMs	O
demonstrate	O
increased	O
co	O
-	O
localization	O
with	O
the	O
autophagy	O
molecule	O
p62	B-GP
,	O
increased	O
autophagosome	O
formation	O
,	O
and	O
increased	O
trafficking	O
to	O
lysosomes	O
compared	O
to	O
untreated	O
CF	B-DS
MDMs	O
.	O

Electron	O
microscopy	O
confirmed	O
IFN	B-GP
-	I-GP
γ	I-GP
promotes	O
double	O
membrane	O
vacuole	O
formation	O
around	O
bacteria	B-OG
in	O
CF	B-DS
MDMs	O
,	O
while	O
only	O
single	O
membrane	O
vacuoles	O
form	O
in	O
untreated	O
CF	B-DS
cells	O
.	O

Bacterial	O
burden	O
is	O
significantly	O
reduced	O
in	O
autophagy	O
stimulated	O
CF	B-DS
MDMs	O
,	O
comparable	O
to	O
non	O
-	O
CF	B-DS
levels	O
.	O

IL	B-GP
-	I-GP
1β	I-GP
production	O
is	O
decreased	O
in	O
CF	B-DS
MDMs	O
after	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
IFN	B-GP
-	I-GP
γ	I-GP
promotes	O
autophagy	O
-	O
mediated	O
clearance	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
human	B-OG
CF	B-DS
macrophages	O
.	O

Introduction	O

Cystic	B-DS
fibrosis	I-DS
(	O
CF	B-DS
)	O
is	O
an	O
inherited	O
,	O
life	O
-	O
limiting	O
disease	O
that	O
causes	O
multi	O
-	O
organ	O
dysfunction	O
characterized	O
by	O
progressive	O
respiratory	B-DS
infections	I-DS
with	O
inspissated	O
mucous	O
[	O
1	O
],	O
[	O
2	O
].	O

Patients	O
with	O
CF	B-DS
can	O
be	O
infected	O
by	O
a	O
variety	O
of	O
pathogens	O
,	O
including	O
the	O
rapidly	O
transmissible	O
Burkholderia	B-OG
cenocepacia	I-OG
[	O
3	O
]–[	O
6	O
].	O
B	B-OG
.	I-OG
cenocepacia	I-OG
is	O
a	O
unique	O
CF	B-DS
pathogen	O
that	O
causes	O
either	O
a	O
distinct	O
clinical	O
phenotype	O
of	O
systemic	O
fatal	O
septicemia	B-DS
or	O
hastened	O
chronic	O
respiratory	O
deterioration	O
with	O
diminished	O
long	O
term	O
survival	O
[	O
7	O
],	O
[	O
8	O
].	O

Therapeutic	O
options	O
are	O
severely	O
limited	O
due	O
to	O
multi	O
-	O
drug	O
resistance	O
and	O
near	O
universal	O
exclusion	O
from	O
lung	O
transplant	O
eligibility	O
due	O
to	O
poor	O
post	O
-	O
transplant	O
survival	O
in	O
chronically	O
infected	O
patients	O
[	O
9	O
]–[	O
13	O
].	O

Macrophages	O
are	O
a	O
first	O
-	O
line	O
defense	O
against	O
pathogens	O
including	O
B	B-OG
.	I-OG
cenocepacia	I-OG
.	O
The	O
vital	O
role	O
of	O
macrophages	O
in	O
CF	B-DS
pathogen	O
interactions	O
,	O
in	O
addition	O
to	O
airway	O
epithelial	O
cells	O
,	O
has	O
been	O
highlighted	O
by	O
several	O
groups	O
[	O
14	O
]–[	O
19	O
].	O

Bacteria	B-OG
survive	O
in	O
CF	B-DS
macrophages	O
despite	O
successful	O
phagocytosis	O
due	O
to	O
links	O
between	O
CF	B-GP
transmembrane	I-GP
conductance	I-GP
regulator	I-GP
(	O
CFTR	B-GP
)	O
dysfunction	O
and	O
impaired	O
phagolysosomal	O
killing	O
[	O
17	O
],	O
[	O
20	O
],	O
[	O
21	O
].	O
B	B-OG
.	I-OG
cenocepacia	I-OG
is	O
also	O
specifically	O
able	O
to	O
evade	O
degradation	O
in	O
CF	B-DS
macrophages	O
leading	O
to	O
severe	O
and	O
persistent	O
inflammation	O
[	O
19	O
],	O
[	O
22	O
],	O
[	O
23	O
].	O

Additionally	O
,	O
in	O
model	O
systems	O
B	B-OG
.	I-OG
cenocepacia	I-OG
replicates	O
inside	O
of	O
macrophages	O
prior	O
to	O
dissemination	O
[	O
24	O
].	O

In	O
conjunction	O
with	O
macrophage	O
defects	O
,	O
CF	B-DS
leads	O
to	O
deficient	O
autophagy	O
through	O
inflammatory	O
mediated	O
cross	O
-	O
linking	O
of	O
the	O
essential	O
beclin	B-GP
-	I-GP
1	I-GP
autophagy	O
initiator	O
interactome	O
[	O
25	O
].	O

Autophagy	O
is	O
a	O
physiologic	O
process	O
that	O
normally	O
augments	O
innate	O
responses	O
to	O
intraphagosomal	O
pathogens	O
and	O
may	O
relate	O
to	O
macrophage	O
clearance	O
defects	O
.	O

Deficient	O
autophagy	O
prevents	O
destruction	O
of	O
engulfed	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
murine	O
CF	B-DS
macrophages	O
[	O
22	O
],	O
[	O
26	O
].	O

Autophagy	O
stimulation	O
by	O
rapamycin	O
reduces	O
murine	O
CF	B-DS
bacterial	O
burden	O
and	O
inflammation	O
[	O
22	O
].	O

Autophagy	O
stimulation	O
with	O
rapamycin	O
also	O
enhances	O
clearance	O
of	O
other	O
major	O
CF	B-DS
pathogens	O
such	O
as	O
Pseudomonas	B-OG
aeruginosa	I-OG
[	O
27	O
]	O
and	O
Staphylococcus	O
aureus	O
[	O
28	O
],	O
but	O
autophagy	O
has	O
not	O
been	O
studied	O
in	O
human	B-OG
CF	B-DS
macrophages	O
.	O

Restoration	O
of	O
functional	O
autophagy	O
with	O
an	O
anti	O
-	O
inflammatory	O
peptide	O
,	O
IDR	O
-	O
1018	O
,	O
decreases	O
inflammation	O
in	O
CF	B-DS
cells	O
[	O
29	O
],	O
and	O
may	O
globally	O
alleviate	O
CF	B-DS
symptoms	O
by	O
releasing	O
sequestered	O
essential	O
autophagy	O
molecules	O
,	O
such	O
as	O
the	O
autophagy	O
adaptor	O
molecule	O
P62	B-GP
/	O
SQSTM1	B-GP
(	O
p62	B-GP
)[	O
30	O
].	O

Relief	O
of	O
sequestered	O
autophagy	O
molecules	O
enabled	O
protein	O
aggregate	O
clearance	O
and	O
improved	O
CFTR	B-GP
trafficking	O
,	O
lending	O
benefits	O
of	O
autophagy	O
-	O
stimulated	O
pathogen	O
clearance	O
[	O
25	O
].	O

Although	O
rapamycin	O
was	O
effective	O
in	O
murine	O
CF	B-DS
studies	O
,	O
systemic	O
side	O
effects	O
of	O
rapamycin	O
in	O
CF	B-DS
[	O
31	O
]	O
and	O
increased	O
development	O
of	O
interstitial	B-DS
lung	I-DS
disease	I-DS
[	O
32	O
]	O
prevent	O
clinical	O
trials	O
.	O

Additionally	O
,	O
autophagy	O
stimulation	O
by	O
immununologics	O
,	O
such	O
as	O
rapamycin	O
,	O
raises	O
questions	O
how	O
this	O
would	O
affect	O
other	O
microorganisms	B-OG
in	O
the	O
lungs	O
of	O
CF	B-DS
patients	O
.	O

Alternatively	O
,	O
IFN	B-GP
-	I-GP
γ	I-GP
has	O
been	O
shown	O
to	O
increase	O
macrophage	O
clearance	O
of	O
apoptotic	O
cells	O
in	O
chronic	B-DS
granulomatous	I-DS
disease	I-DS
(	O
CGD	B-DS
)	O
[	O
33	O
],	O
and	O
is	O
used	O
prophylactically	O
in	O
CGD	B-DS
patients	O
to	O
prevent	O
acquisition	O
of	O
severe	O
infections	B-DS
such	O
as	O
Burkholderia	B-OG
species	O
[	O
34	O
],	O
[	O
35	O
].	O

CGD	B-DS
,	O
the	O
only	O
other	O
known	O
clinical	O
disease	O
commonly	O
affected	O
by	O
Burkholderia	B-OG
species	O
,	O
also	O
has	O
known	O
phagocytic	O
killing	O
defects	O
[	O
36	O
],	O
[	O
37	O
]	O
and	O
was	O
recently	O
shown	O
to	O
have	O
deficient	O
autophagic	O
responses	O
to	O
B	B-OG
.	I-OG
cenocepacia	I-OG
[	O
38	O
].	O

Furthermore	O
,	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
enhances	O
the	O
autophagy	O
response	O
in	O
macrophages	O
derived	O
from	O
non	O
-	O
CGD	B-DS
patients	O
resulting	O
in	O
clearance	O
of	O
pathogens	O
that	O
evade	O
typical	O
phagocytic	O
degradation	O
[	O
39	O
].	O

IFN	B-GP
-	I-GP
γ	I-GP
therapy	O
is	O
well	O
tolerated	O
in	O
CGD	B-DS
patients	O
who	O
have	O
altered	O
immune	O
functions	O
and	O
polymicrobial	B-DS
infections	I-DS
similar	O
to	O
CF	B-DS
[	O
34	O
],	O
[	O
40	O
].	O

Although	O
a	O
trial	O
of	O
inhaled	O
IFN	B-GP
-	I-GP
γ	I-GP
in	O
CF	B-DS
patients	O
with	O
mild	O
to	O
moderate	O
disease	O
did	O
not	O
prove	O
effective	O
in	O
altering	O
lung	O
function	O
[	O
41	O
],	O
IFN	B-GP
-	I-GP
γ	I-GP
has	O
never	O
been	O
studied	O
systemically	O
in	O
CF	B-DS
,	O
or	O
specifically	O
in	O
B	B-OG
.	I-OG
cenocepacia	I-OG
infected	O
patients	O
,	O
who	O
may	O
require	O
more	O
than	O
local	O
lung	O
treatment	O
.	O

We	O
hypothesize	O
that	O
due	O
to	O
known	O
defects	O
in	O
CF	B-DS
macrophage	O
autophagy	O
,	O
IFN	B-GP
-	I-GP
γ	I-GP
will	O
reduce	O
B	B-OG
.	I-OG
cenocepacia	I-OG
burden	O
in	O
human	B-OG
CF	B-DS
macrophages	O
through	O
more	O
effective	O
killing	O
and	O
enhanced	O
autophagy	O
that	O
degrade	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
nascent	O
vacuoles	O
.	O

Materials	O
and	O
Methods	O

Bacterial	O
Strains	O
and	O
Culture	O

Burkholderia	B-OG
cenocepacia	I-OG
strain	I-OG
k56	I-OG
-	I-OG
2	I-OG
is	O
a	O
clinical	O
isolate	O
of	O
the	O
ET12	O
lineage	O
originally	O
isolated	O
from	O
a	O
CF	B-DS
patient	O
’	O
s	O
sputum	O
.	O

The	O
strain	O
was	O
tagged	O
dsRED	O
and	O
grown	O
in	O
Luria	O
-	O
Bertani	O
(	O
LB	O
)	O
broth	O
at	O
37	O
°	O
C	O
overnight	O
with	O
high	O
amplitude	O
shaking	O
.	O

The	O
B	B-OG
.	I-OG
cenocepacia	I-OG
MHK1	I-OG
strain	O
is	O
derived	O
from	O
k56	O
-	O
2	O
and	O
has	O
a	O
mutation	O
in	O
an	O
antibiotic	B-GP
efflux	I-GP
pump	I-GP
that	O
confers	O
gentamicin	O
sensitivity	O
,	O
but	O
does	O
not	O
alter	O
the	O
trafficking	O
of	O
the	O
mutant	O
in	O
macrophages	O
[	O
42	O
].	O

For	O
colony	O
forming	O
unit	O
(	O
CFU	O
)	O
analysis	O
,	O
50	O
µg	O
/	O
ml	O
gentamicin	O
(	O
Invitrogen	O
,	O
3564	O
)	O
was	O
added	O
for	O
0	O
.	O
5	O
hours	O
as	O
described	O
previously	O
[	O
43	O
].	O

To	O
enumerate	O
intracellular	O
bacteria	B-OG
,	O
infected	O
macrophages	O
were	O
lysed	O
with	O
ice	O
-	O
cold	O
PBS	O
(	O
Invitrogen	O
,	O
14190	O
)	O
at	O
designated	O
times	O
.	O

Extracellular	O
bacteria	B-OG
were	O
enumerated	O
directly	O
from	O
cell	O
supernatants	O
during	O
macrophage	O
viability	O
assays	O
.	O

Recovered	O
bacteria	B-OG
were	O
quantified	O
by	O
plating	O
serial	O
dilutions	O
on	O
LB	O
agar	O
plates	O
and	O
counting	O
colonies	O
using	O
the	O
Acolyte	O
Colony	O
Counter	O
,	O
5710	O
/	O
SYN	O
.	O

Human	B-OG
Monocyte	O
-	O
Derived	O
Macrophages	O
(	O
MDMs	O
)	O
–	O
Ethics	O
Statement	O

Human	B-OG
subjects	O
underwent	O
written	O
informed	O
consent	O
for	O
blood	O
donation	O
at	O
the	O
Nationwide	O
Children	O
’	O
s	O
Hospital	O
as	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
Nationwide	O
Children	O
’	O
s	O
Hospital	O
.	O

Written	O
consent	O
from	O
legal	O
guardians	O
of	O
minors	O
was	O
obtained	O
as	O
well	O
as	O
written	O
assent	O
from	O
minors	O
aged	O
9	O
to	O
17	O
years	O
.	O

Blood	O
was	O
drawn	O
in	O
heparinized	O
tubes	O
.	O

Exclusion	O
criteria	O
included	O
history	O
of	O
B	B-OG
.	I-OG
cepacia	I-OG
complex	I-OG
culture	O
positivity	O
,	O
chronic	B-DS
immunosuppression	I-DS
,	O
CFTR	B-GP
modulator	O
use	O
,	O
and	O
history	O
of	O
transplantation	O
.	O

Chronic	O
azithromycin	O
was	O
the	O
only	O
immunomodulatory	O
medicine	O
taken	O
by	O
some	O
subjects	O
during	O
the	O
study	O
period	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
isolated	O
from	O
27	O
CF	B-DS
and	O
27	O
non	O
-	O
CF	B-DS
healthy	O
controls	O
.	O

Monocytes	O
were	O
separated	O
using	O
a	O
Ficol	O
gradient	O
via	O
Lymphocyte	O
Separation	O
Medium	O
(	O
Corning	O
,	O
25	O
-	O
072	O
-	O
CV	O
).	O

Isolated	O
monocytes	O
were	O
re	O
-	O
suspended	O
in	O
RPMI	O
(	O
Gibco	O
,	O
22400	O
-	O
089	O
)	O
and	O
10	O
%	O
human	B-OG
AB	O
serum	O
(	O
Lonza	O
,	O
14	O
-	O
490E	O
)	O
to	O
a	O
concentration	O
of	O
2	O
×	O
106	O
cells	O
/	O
mL	O
and	O
incubated	O
for	O
5	O
days	O
at	O
37	O
°	O
C	O
to	O
derive	O
macrophages	O
.	O

Macrophages	O
were	O
then	O
infected	O
with	O
B	B-OG
.	I-OG
cenocepacia	I-OG
strain	I-OG
k56	I-OG
-	I-OG
2	I-OG
at	O
a	O
multiplicity	O
of	O
infection	B-DS
(	O
MOI	O
)	O
ranging	O
from	O
2	O
–	O
10	O
over	O
the	O
stated	O
times	O
.	O

Reagents	O

IFN	B-GP
-	I-GP
γ	I-GP
(	O
eBioscience	O
,	O
14	O
-	O
8319	O
-	O
80	O
)	O
was	O
used	O
at	O
a	O
concentration	O
of	O
200	O
ηg	O
/	O
ml	O
based	O
upon	O
effectiveness	O
in	O
trial	O
experiments	O
.	O

Rapamycin	O
(	O
LC	O
laboratories	O
,	O
AY	O
-	O
22989	O
)	O
was	O
added	O
to	O
the	O
cells	O
at	O
a	O
concentration	O
of	O
25	O
µg	O
/	O
ml	O
.	O

Treatments	O
were	O
added	O
1	O
hour	O
post	O
infection	B-DS
and	O
the	O
cells	O
were	O
allowed	O
to	O
incubate	O
for	O
2	O
,	O
4	O
,	O
and	O
24hours	O
before	O
obtaining	O
results	O
.	O

Two	O
mM	O
3	O
-	O
methyladenine	O
(	O
3MA	O
,	O
M9281	O
)	O
and	O
10	O
nM	O
Bafilomycin	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
B1793	O
)	O
were	O
added	O
one	O
hour	O
prior	O
to	O
infection	B-DS
in	O
inhibitor	O
experiments	O
.	O

Immunoblotting	O

Macrophage	O
supernatants	O
were	O
removed	O
post	O
treatment	O
and	O
the	O
cells	O
were	O
washed	O
twice	O
with	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
).	O

The	O
cells	O
were	O
lysed	O
in	O
lysis	O
buffer	O
and	O
primed	O
with	O
a	O
protease	B-GP
inhibitor	O
(	O
Roche	O
Applied	O
Science	O
,	O
10	O
-	O
519	O
-	O
978	O
-	O
001	O
).	O

Then	O
,	O
30	O
ug	O
of	O
protein	O
was	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
transferred	O
onto	O
polyvinylidene	O
difluoride	O
(	O
PVDF	O
)	O
membranes	O
.	O

Membranes	O
were	O
immunoblotted	O
for	O
LC3	B-GP
(	O
Sigma	O
-	O
Aldrich	O
,	O
L8918	O
),	O
p62	B-GP
(	O
Sigma	O
-	O
Aldrich	O
,	O
P0067	O
),	O
beclin	B-GP
-	I-GP
1	I-GP
(	O
Abcam	O
,	O
ab51031	O
),	O
actin	B-GP
(	O
Abcam	O
,	O
ab8226	O
-	O
100	O
),	O
IFNGR1	B-GP
(	O
Abcam	O
,	O
ab61179	O
),	O
IFNGRbeta	B-GP
(	O
Abcam	O
,	O
ab84524	O
),	O
and	O
calreticulin	B-GP
(	O
Stressgen	O
,	O
#	O
SPA	O
-	O
600	O
).	O

Protein	O
bands	O
were	O
detected	O
with	O
HRP	B-GP
-	O
conjugated	O
secondary	O
antibodies	B-GP
visualized	O
using	O
enhanced	O
chemiluminescent	O
(	O
ECL	O
)	O
reagents	O
(	O
Life	O
Sciences	O
,	O
RPN2106	O
).	O

Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
)	O

MDM	O
culture	O
supernatants	O
were	O
clarified	O
and	O
stored	O
at	O
−	O
20	O
°	O
C	O
until	O
assayed	O
for	O
cytokine	B-GP
content	O
.	O

MDMs	O
were	O
infected	O
for	O
4	O
and	O
24	O
hours	O
with	O
k56	O
-	O
2	O
.	O

The	O
quantification	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
and	O
IL	B-GP
-	I-GP
10	I-GP
in	O
supernatants	O
was	O
determined	O
by	O
sandwich	O
ELISA	O
following	O
the	O
manufacturer	O
’	O
s	O
protocol	O
(	O
R	O
&	O
D	O
system	O
Inc	O
,	O
DY285	O
)	O
as	O
previously	O
described	O
[	O
43	O
].	O

Cytotoxicity	O

MDMs	O
were	O
infected	O
with	O
k56	O
-	O
2	O
for	O
4	O
and	O
24hours	O
and	O
the	O
culture	O
supernatants	O
were	O
collected	O
and	O
centrifuged	O
.	O

Histone	B-GP
-	O
associated	O
DNA	O
fragments	O
were	O
detected	O
using	O
a	O
cytotoxicity	O
detection	O
photometric	O
assay	O
kit	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocol	O
(	O
Roche	O
Applied	O
Science	O
,	O
11	O
644	O
793	O
001	O
).	O

All	O
experiments	O
were	O
performed	O
in	O
at	O
least	O
triplicate	O
.	O

Additionally	O
,	O
macrophage	O
viability	O
was	O
assessed	O
via	O
naphthol	O
staining	O
.	O

MDMs	O
were	O
plated	O
in	O
24	O
-	O
well	O
plates	O
,	O
infected	O
for	O
1	O
h	O
,	O
then	O
treated	O
for	O
24	O
h	O
.	O

Cells	O
were	O
washed	O
and	O
treated	O
with	O
1	O
%	O
Cetavlon	O
in	O
0	O
.	O
1	O
M	O
citric	O
acid	O
with	O
0	O
.	O
05	O
%	O
Napthol	O
blue	O
black	O
(	O
Sigma	O
-	O
Aldrich	O
),	O
pH	O
2	O
.	O
2	O
,	O
for	O
15	O
min	O
at	O
room	O
temperature	O
.	O

Stained	O
nuclei	O
were	O
enumerated	O
on	O
a	O
haemacytometer	O
using	O
phase	O
-	O
contrast	O
microscopy	O
.	O

Confocal	O
Microscopy	O

Confocal	O
microscopy	O
sample	O
were	O
analyzed	O
with	O
an	O
Olympus	O
FV10i	O
Spectral	O
Confocal	O
microscope	O
.	O
Two	O
million	O
MDMs	O
were	O
cultured	O
on	O
12	O
mm	O
glass	O
cover	O
slips	O
in	O
24	O
-	O
well	O
tissue	O
culture	O
plates	O
and	O
infected	O
synchronously	O
with	O
k56	O
-	O
2	O
at	O
an	O
MOI	O
of	O
2	O
or	O
10	O
.	O

Nuclei	O
were	O
stained	O
with	O
the	O
nucleic	O
acid	O
dye	O
4	O
′,	O
6	O
′-	O
diamino	O
-	O
2	O
-	O
phenylindole	O
(	O
DAPI	O
)	O
blue	O
for	O
imaging	O
.	O

LC3	B-GP
stained	O
green	O
with	O
a	O
cleaved	O
LC3	B-GP
antibody	B-GP
detection	O
(	O
Abgent	O
,	O
AP1805a	O
).	O

Lysosomes	O
were	O
stained	O
green	O
with	O
Lysotracker	O
Green	O
(	O
Invitrogen	O
,	O
L7526	O
).	O

p62	B-GP
was	O
detected	O
with	O
a	O
green	O
fluorescent	O
ligand	O
(	O
BD	O
Bioscience	O
,	O
610832	O
).	O

At	O
least	O
one	O
hundred	O
macrophages	O
were	O
scored	O
for	O
each	O
condition	O
with	O
scoring	O
verified	O
by	O
independent	O
study	O
members	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
at	O
least	O
triplicate	O
.	O

Transmission	O
Electron	O
Microscopy	O

TEM	O
Images	O
were	O
obtained	O
using	O
a	O
FEI	O
Technai	O
G2	O
Spirit	O
transmission	O
electron	O
microscope	O
(	O
FEI	O
,	O
USA	O
),	O
Macrofire	O
(	O
Optronics	O
)	O
digital	O
camera	O
and	O
AMT	O
image	O
capture	O
Software	O
with	O
assistance	O
from	O
the	O
Campus	O
Microscopy	O
and	O
Imaging	O
Facility	O
(	O
CMIF	O
)	O
at	O
The	O
Ohio	O
State	O
University	O
.	O

MDMs	O
were	O
isolated	O
and	O
infected	O
with	O
k56	O
-	O
2	O
at	O
an	O
MOI	O
of	O
10	O
for	O
1	O
hour	O
prior	O
to	O
24	O
hour	O
experimental	O
treatments	O
.	O

Cells	O
were	O
cultured	O
on	O
Permanox	O
(	O
Lab	O
-	O
Tek	O
)	O
chamber	O
slides	O
and	O
fixed	O
with	O
2	O
.	O
5	O
%	O
gluteraldehyde	O
in	O
0	O
.	O
1	O
M	O
phosphate	O
buffer	O
with	O
0	O
.	O
1	O
M	O
sucrose	O
.	O

Slides	O
were	O
post	O
fixed	O
with	O
1	O
%	O
osmium	O
tetroxide	O
in	O
phosphate	O
buffer	O
then	O
en	O
bloc	O
stained	O
with	O
2	O
%	O
uranyl	O
acetate	O
in	O
10	O
%	O
ethanol	O
,	O
dehydrated	O
in	O
a	O
graded	O
series	O
of	O
ethanols	O
and	O
embedded	O
in	O
Eponate	O
12	O
epoxy	O
resin	O
(	O
Ted	O
Pella	O
Inc	O
.,	O
USA	O
).	O

Ultrathin	O
sections	O
were	O
cut	O
on	O
a	O
Leica	O
EM	O
UC6	O
ultra	O
microtome	O
(	O
Leica	O
microsystems	O
,	O
Germany	O
),	O
collected	O
on	O
copper	O
grids	O
,	O
and	O
then	O
stained	O
with	O
lead	O
citrate	O
and	O
uranyl	O
acetate	O
.	O

Statistical	O
Analysis	O

Statistical	O
analysis	O
was	O
performed	O
using	O
GraphPad	O
Prism	O
software	O
(	O
version	O
6	O
.	O
0	O
).	O

Statistical	O
significance	O
was	O
determined	O
with	O
a	O
two	O
-	O
tailed	O
p	O
<	O
0	O
.	O
05	O
.	O

Mann	O
-	O
Whitney	O
was	O
used	O
for	O
non	O
-	O
parametric	O
measurements	O
,	O
and	O
ANOVA	O
was	O
used	O
where	O
appropriate	O
.	O

Results	O

Patient	O
Demographics	O

Subject	O
demographics	O
are	O
described	O
in	O
Table	O
1	O
.	O

CF	B-DS
and	O
non	O
-	O
CF	B-DS
subjects	O
were	O
similar	O
in	O
terms	O
of	O
ethnicity	O
(	O
100	O
%	O
Caucasian	O
)	O
and	O
mean	O
age	O
(	O
30	O
.	O
4	O
±	O
11	O
.	O
5	O
years	O
vs	O
.	O
33	O
.	O
5	O
±	O
9	O
.	O
2	O
years	O
,	O
p	O
=	O
0	O
.	O
53	O
).	O

Subjects	O
with	O
CF	B-DS
had	O
a	O
mean	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
FEV1	O
)	O
%	O
predicted	O
of	O
57	O
.	O
1	O
%,	O
indicative	O
of	O
moderately	O
severe	O
lung	O
function	O
at	O
the	O
time	O
of	O
sampling	O
.	O

81	O
%	O
of	O
CF	B-DS
patients	O
had	O
chronic	O
respiratory	O
cultures	O
positive	O
for	O
P	B-OG
.	I-OG
aeruginosa	I-OG
,	O
and	O
48	O
%	O
had	O
methicillin	B-OG
resistant	I-OG
S	I-OG
.	I-OG
aureus	I-OG
(	O
MRSA	B-OG
).	O

Importantly	O
,	O
48	O
%	O
of	O
subjects	O
were	O
on	O
chronic	O
azithromycin	O
prophylaxis	O
,	O
and	O
this	O
treatment	O
was	O
not	O
noted	O
to	O
influence	O
the	O
experiments	O
below	O
.	O

Azithromycin	O
has	O
been	O
show	O
to	O
block	O
autophagy	O
in	O
CF	B-DS
macrophages	O
in	O
vitro	O
[	O
44	O
],	O
but	O
CF	B-DS
Patient	O
Registry	O
data	O
does	O
not	O
support	O
an	O
increased	O
risk	O
of	O
mycobacterial	B-DS
infections	I-DS
for	O
those	O
on	O
chronic	O
azithromycin	O
as	O
proposed	O
in	O
the	O
study	O
by	O
Renna	O
and	O
colleagues	O
[	O
45	O
].	O

Cell	O
cultures	O
in	O
our	O
experiments	O
were	O
not	O
further	O
treated	O
with	O
azithromycin	O
.	O

Patient	O
Demographics	O
.	O

non	O
CF	B-DS
patients	O
(	O
n	O
=	O
27	O
)	O

CF	B-DS
patients	O
(	O
n	O
=	O
27	O
)	O

Mean	O
age	O
(	O
years	O
±	O
st	O
.	O
dev	O
.)	O

33	O
.	O
5	O
±	O
9	O
.	O
2	O

30	O
.	O
4	O
±	O
11	O
.	O
5	O

Males	O

30	O
%	O

59	O
%	O

Caucasian	O

100	O
%	O

100	O
%	O

Mean	O
FEV1	O
(%	O
predicted	O
)	O

N	O
/	O
A	O

57	O
.	O
1	O
±	O
21	O
.	O
4	O

Pseudomonas	O
colonization	O

N	O
/	O
A	O

81	O
%	O

MRSA	B-OG
colonization	O

N	O
/	O
A	O

48	O
%	O

IFN	B-GP
-	I-GP
γ	I-GP
Production	O
is	O
Reduced	O
in	O
CF	B-DS
PBMCs	O

IFN	B-GP
-	I-GP
γ	I-GP
effectively	O
stimulates	O
autophagic	O
responses	O
in	O
macrophages	O
[	O
46	O
],	O
[	O
47	O
].	O

However	O
,	O
CF	B-DS
cells	O
insufficiently	O
produce	O
IFN	B-GP
-	I-GP
γ	I-GP
in	O
response	O
to	O
another	O
pathogen	O
,	O
P	B-OG
.	I-OG
aeruginosa	I-OG
[	O
48	O
].	O

To	O
determine	O
if	O
IFN	B-GP
-	I-GP
γ	I-GP
is	O
differentially	O
produced	O
in	O
CF	B-DS
in	O
response	O
to	O
B	B-OG
.	I-OG
cenocepacia	I-OG
,	O
IFN	B-GP
-	I-GP
γ	I-GP
was	O
measured	O
in	O
the	O
serum	O
of	O
CF	B-DS
and	O
non	O
-	O
CF	B-DS
subjects	O
prior	O
to	O
macrophage	O
isolation	O
and	O
in	O
PBMC	O
culture	O
supernatants	O
with	O
and	O
without	O
24	O
hour	O
B	B-DS
.	I-DS
cenocepacia	I-DS
infection	I-DS
.	O

Mean	O
serum	O
levels	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
were	O
non	O
-	O
significantly	O
lower	O
in	O
CF	B-DS
versus	O
non	O
-	O
CF	B-DS
subjects	O
(	O
56	O
.	O
6	O
±	O
6	O
.	O
6	O
vs	O
.	O
78	O
.	O
9	O
±	O
10	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
08	O
,	O
Figure	O
1A	O
).	O

Infected	O
non	O
-	O
CF	B-DS
PBMC	O
supernatants	O
displayed	O
significantly	O
higher	O
IFN	B-GP
-	I-GP
γ	I-GP
levels	O
compared	O
to	O
uninfected	O
,	O
whereas	O
there	O
was	O
no	O
change	O
in	O
IFN	B-GP
-	I-GP
γ	I-GP
production	O
between	O
uninfected	O
and	O
infected	O
CF	B-DS
PBMCs	O
(	O
Figure	O
1B	O
).	O

Uninfected	O
CF	B-DS
and	O
non	O
-	O
CF	B-DS
PBMC	O
IFN	B-GP
-	I-GP
γ	I-GP
levels	O
were	O
both	O
slightly	O
higher	O
than	O
serum	O
levels	O
.	O

There	O
was	O
no	O
difference	O
in	O
IFN	B-GP
-	I-GP
γ	I-GP
production	O
between	O
CF	B-DS
patients	O
on	O
azithromycin	O
therapy	O
and	O
those	O
not	O
(	O
figure	O
S1A	O
).	O

Additionally	O
,	O
there	O
was	O
no	O
difference	O
in	O
IFN	B-GP
-	I-GP
γ	I-GP
receptor	I-GP
expression	O
during	O
infection	B-DS
between	O
IFN	B-GP
-	I-GP
γ	I-GP
treated	O
and	O
non	O
-	O
treated	O
MDMs	O
as	O
measured	O
by	O
immunoblotting	O
(	O
Figures	O
1C	O
,	O
1D	O
).	O

Our	O
results	O
are	O
consistent	O
with	O
studies	O
from	O
P	B-OG
.	I-OG
aeruginosa	I-OG
[	O
48	O
],	O
suggesting	O
a	O
defective	O
host	O
CF	B-DS
IFN	B-GP
-	I-GP
γ	I-GP
response	O
to	O
multiple	O
pathogens	O
in	O
CF	B-DS
.	O

IFN	B-GP
-	I-GP
γ	I-GP
is	O
deficiently	O
produced	O
in	O
CF	B-DS
PBMCs	O
in	O
response	O
to	O
B	B-OG
.	I-OG
cenocepacia	I-OG
.	O

1A	O
)	O
IFN	B-GP
-	I-GP
γ	I-GP
levels	O
from	O
the	O
serum	O
of	O
14	O
non	O
-	O
CF	B-DS
and	O
14	O
CF	B-DS
patients	O
at	O
the	O
time	O
of	O
blood	O
donation	O
,	O
p	O
=	O
0	O
.	O
056	O
,	O
n	O
=	O
14	O
subjects	O
for	O
each	O
condition	O
,	O
Mann	O
-	O
Whitney	O
testing	O
.	O

1B	O
)	O
IFN	B-GP
-	I-GP
γ	I-GP
production	O
from	O
PBMC	O
24	O
hour	O
cell	O
supernatants	O
from	O
CF	B-DS
and	O
non	O
-	O
CF	B-DS
patients	O
.	O

NT	O
represents	O
uninfected	O
cells	O
,	O
and	O
k56	O
were	O
infected	O
with	O
B	B-OG
.	I-OG
cenocepacia	I-OG
k56	I-OG
-	I-OG
2	I-OG
.	O
n	O
=	O
8	O
subjects	O
for	O
NT	O
and	O
10	O
subjects	O
k56	O
,	O
Mann	O
-	O
Whitney	O
testing	O
.	O

1C	O
)	O
Immunoblot	O
for	O
IFN	B-GP
-	I-GP
receptor	I-GP
1	I-GP
from	O
cell	O
lysates	O
of	O
MDMs	O
infected	O
with	O
k56	O
-	O
2	O
+/−	O
treatment	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
.	O

1D	O
)	O
Immunoblot	O
for	O
IFN	B-GP
-	I-GP
receptor	I-GP
β	I-GP
from	O
cell	O
lysates	O
of	O
MDMs	O
infected	O
with	O
k56	O
-	O
2	O
+/−	O
treatment	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
.	O

IFN	B-GP
-	I-GP
γ	I-GP
Increases	O
B	B-OG
.	I-OG
cenocepacia	I-OG
Co	O
-	O
localization	O
with	O
p62	B-GP

p62	B-GP
is	O
an	O
essential	O
intracellular	O
protein	O
that	O
targets	O
cargo	O
for	O
autophagy	O
as	O
well	O
as	O
regulates	O
signaling	O
pathways	O
involved	O
in	O
cell	O
survival	O
and	O
/	O
or	O
death	O
[	O
49	O
].	O

This	O
docking	O
molecule	O
is	O
required	O
for	O
targeting	O
B	B-OG
.	I-OG
cenocepacia	I-OG
to	O
autophagosomes	O
in	O
a	O
murine	O
model	O
[	O
26	O
],	O
however	O
its	O
mechanism	O
of	O
action	O
in	O
human	B-OG
cells	O
infected	O
with	O
B	B-OG
.	I-OG
cenocepacia	I-OG
is	O
unknown	O
.	O

Using	O
confocal	O
microscopy	O
,	O
we	O
investigated	O
how	O
p62	B-GP
targets	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
human	B-OG
CF	B-DS
macrophages	O
by	O
examining	O
MDMs	O
for	O
co	O
-	O
localization	O
of	O
bacteria	B-OG
with	O
p62	B-GP
after	O
a	O
24	O
hour	O
infection	B-DS
.	O

MDMs	O
were	O
stimulated	O
with	O
rapamycin	O
or	O
IFN	B-GP
-	I-GP
γ	I-GP
for	O
the	O
duration	O
of	O
infection	B-DS
.	O

Untreated	O
CF	B-DS
macrophages	O
demonstrated	O
significantly	O
less	O
median	O
co	O
-	O
localization	O
with	O
p62	B-GP
compared	O
to	O
non	O
-	O
CF	B-DS
macrophages	O
(	O
16	O
.	O
8	O
%	O
(	O
10	O
.	O
1	O
–	O
19	O
.	O
1	O
)	O
vs	O
.	O
37	O
.	O
0	O
%	O
(	O
34	O
.	O
9	O
–	O
40	O
.	O
0	O
),	O
p	O
=	O
0	O
.	O
016	O
,	O
Figures	O
2A	O
,	O
B	O
).	O

IFN	B-GP
-	I-GP
γ	I-GP
or	O
rapamycin	O
treatment	O
significantly	O
increased	O
median	O
bacterial	O
co	O
-	O
localization	O
with	O
p62	B-GP
in	O
CF	B-DS
human	B-OG
MDMs	O
(	O
CF	B-DS
IFN	B-GP
-	I-GP
γ	I-GP
32	O
.	O
7	O
%	O
(	O
25	O
.	O
2	O
–	O
33	O
.	O
4	O
),	O
p	O
=	O
0	O
.	O
006	O
,	O
CF	B-DS
rapamycin	O
26	O
.	O
3	O
%	O
(	O
22	O
.	O
4	O
–	O
47	O
.	O
4	O
),	O
p	O
=	O
0	O
.	O
008	O
,	O
Figures	O
2A	O
,	O
B	O
)	O
nearing	O
non	O
-	O
CF	B-DS
levels	O
.	O

p62	B-GP
levels	O
detected	O
by	O
western	O
blotting	O
are	O
increased	O
in	O
uninfected	O
and	O
infected	O
CF	B-DS
MDMs	O
compared	O
to	O
non	O
-	O
CF	B-DS
MDMs	O
(	O
Figure	O
2C	O
).	O

Twenty	O
-	O
four	O
hour	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
of	O
non	O
-	O
CF	B-DS
and	O
CF	B-DS
MDMs	O
resulted	O
in	O
a	O
decrement	O
in	O
p62	B-GP
accumulation	O
(	O
Figure	O
2C	O
).	O

To	O
ensure	O
that	O
initiation	O
of	O
the	O
beclin	B-GP
-	I-GP
1	I-GP
interactome	O
was	O
not	O
influencing	O
p62	B-GP
expression	O
,	O
beclin	B-GP
-	I-GP
1	I-GP
was	O
measured	O
via	O
immunoblotting	O
and	O
confocal	O
microscopy	O
after	O
24	O
hour	O
infection	B-DS
.	O

There	O
was	O
no	O
difference	O
in	O
beclin	B-GP
-	I-GP
1	I-GP
levels	O
between	O
CF	B-DS
and	O
non	O
CF	B-DS
MDMs	O
(	O
Figure	O
2C	O
,	O
confocal	O
not	O
shown	O
).	O

Altogether	O
,	O
this	O
data	O
suggested	O
that	O
p62	B-GP
is	O
either	O
sequestered	O
or	O
inefficiently	O
utilized	O
by	O
human	B-OG
CF	B-DS
MDMs	O
,	O
and	O
IFN	B-GP
-	I-GP
γ	I-GP
can	O
alleviate	O
this	O
undesirable	O
phenotype	O
in	O
CF	B-DS
cells	O
.	O

IFN	B-GP
-	I-GP
γ	I-GP
increases	O
B	B-OG
.	I-OG
cenocepacia	I-OG
co	O
-	O
localization	O
with	O
p62	B-GP
and	O
decreases	O
p62	B-GP
accumulation	O
in	O
CF	B-DS
.	O

2A	O
)	O
Confocal	O
microscopy	O
for	O
non	O
-	O
CF	B-DS
and	O
CF	B-DS
macrophages	O
infected	O
with	O
m	O
-	O
RFP	B-GP
expressing	O
k56	O
-	O
2	O
.	O

IFN	B-GP
-	I-GP
y	I-GP
or	O
rapamycin	O
treatment	O
was	O
administered	O
after	O
1	O
hour	O
of	O
infection	B-DS
for	O
a	O
24	O
hour	O
treatment	O
period	O
.	O

p62	B-GP
is	O
stained	O
green	O
,	O
and	O
macrophage	O
nuclei	O
are	O
stained	O
blue	O
with	O
DAPI	O
.	O

Co	O
-	O
localization	O
of	O
bacteria	B-OG
with	O
p62	B-GP
is	O
noted	O
in	O
yellow	O
in	O
the	O
bottom	O
panel	O
.	O

2B	O
)	O
The	O
percentage	O
of	O
bacterial	O
co	O
-	O
localization	O
with	O
p62	B-GP
was	O
scored	O
for	O
over	O
100	O
macrophages	O
per	O
condition	O
,	O
n	O
=	O
5	O
subjects	O
per	O
condition	O
,	O
Mann	O
-	O
Whitney	O
testing	O
.	O

2C	O
)	O
Immunoblot	O
for	O
non	O
-	O
CF	B-DS
and	O
CF	B-DS
macrophages	O
demonstrating	O
p62	B-GP
accumulation	O
in	O
CF	B-DS
with	O
reduction	O
during	O
IFN	B-GP
-	I-GP
y	I-GP
therapy	O
,	O
representative	O
of	O
5	O
subjects	O
.	O

Immunoblot	O
of	O
beclin	B-GP
-	I-GP
1	I-GP
levels	O
for	O
non	O
-	O
CF	B-DS
and	O
CF	B-DS
macrophages	O
from	O
cell	O
lysates	O
of	O
control	O
(	O
NT	O
)	O
and	O
MDMs	O
infected	O
with	O
k56	O
-	O
2	O
+/−	O
treatment	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
n	O
=	O
4	O
.	O

Autophagic	O
Flux	O
is	O
Enhanced	O
by	O
IFN	B-GP
-	I-GP
γ	I-GP
in	O
CF	B-DS
MDMs	O

Autophagic	O
flux	O
is	O
deficient	O
in	O
CF	B-DS
cells	O
[	O
25	O
],	O
[	O
30	O
].	O

Microtubule	B-GP
-	I-GP
associated	I-GP
proteins	I-GP
1A	I-GP
/	I-GP
1B	I-GP
light	I-GP
chain	I-GP
3A	I-GP
(	O
LC3	B-GP
)	O
can	O
be	O
monitored	O
to	O
assess	O
autophagosome	O
formation	O
and	O
flux	O
.	O

During	O
the	O
autophagic	O
process	O
,	O
cytosolic	O
LC3	B-GP
(	O
LC3	B-GP
-	I-GP
I	I-GP
)	O
is	O
conjugated	O
to	O
phosphatidylethanolamine	O
to	O
form	O
LC3	B-GP
-	I-GP
II	I-GP
,	O
which	O
is	O
then	O
recruited	O
to	O
the	O
autophagosomal	O
membrane	O
.	O

We	O
analyzed	O
LC3	B-GP
concentrations	O
by	O
immunoblotting	O
to	O
monitor	O
the	O
conversion	O
of	O
LC3	B-GP
-	I-GP
I	I-GP
to	O
LC3	B-GP
-	I-GP
II	I-GP
,	O
as	O
well	O
as	O
depletion	O
/	O
accumulation	O
of	O
the	O
proteins	O
to	O
assist	O
in	O
determination	O
of	O
turnover	O
of	O
proteins	O
.	O

During	O
basal	O
,	O
uninfected	O
conditions	O
(	O
NT	O
),	O
CF	B-DS
macrophages	O
demonstrated	O
persistence	O
of	O
increased	O
LC3	B-GP
-	I-GP
1	I-GP
over	O
24	O
hours	O
compared	O
to	O
non	O
CF	B-DS
as	O
evidence	O
by	O
high	O
proportion	O
of	O
LC31	B-GP
relative	O
to	O
total	O
LC3	B-GP
(	O
Figures	O
3A	O
,	O
3B	O
).	O

Infection	B-DS
with	O
k56	O
-	O
2	O
leads	O
to	O
persistently	O
elevated	O
LC3	B-GP
-	I-GP
1	I-GP
levels	O
in	O
CF	B-DS
by	O
24	O
hours	O
compared	O
to	O
non	O
CF	B-DS
,	O
but	O
to	O
a	O
lesser	O
extent	O
than	O
basal	O
conditions	O
(	O
Figure	O
3B	O
).	O

LC31	B-GP
levels	O
are	O
seen	O
to	O
decrease	O
in	O
CF	B-DS
similar	O
to	O
non	O
CF	B-DS
levels	O
by	O
24	O
hours	O
with	O
the	O
use	O
of	O
either	O
IFN	B-GP
-	I-GP
γ	I-GP
or	O
rapamycin	O
(	O
Figure	O
3B	O
).	O

Specific	O
autophagy	O
inhibitors	O
were	O
used	O
to	O
monitor	O
treatment	O
effects	O
.	O

The	O
addition	O
of	O
bafilomycin	O
to	O
inhibit	O
autophagolysosomal	O
fusion	O
via	O
inhibiting	O
vacuolar	B-GP
H	I-GP
+	I-GP
ATPase	I-GP
(	O
V	B-GP
-	I-GP
ATPase	I-GP
)	O
caused	O
an	O
increase	O
in	O
LC3	B-GP
-	I-GP
1	I-GP
in	O
CF	B-DS
at	O
4	O
and	O
24	O
hours	O
(	O
Figures	O
3A	O
,	O
3B	O
),	O
reversing	O
the	O
effects	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
.	O

The	O
addition	O
of	O
3	O
-	O
methyladenine	O
(	O
3	O
-	O
MA	O
)	O
to	O
block	O
autophagosome	O
formation	O
via	O
inhibiting	O
type	B-GP
III	I-GP
Phosphatidylinositol	I-GP
3	I-GP
-	I-GP
kinases	I-GP
had	O
a	O
similar	O
,	O
but	O
lesser	O
effect	O
in	O
CF	B-DS
on	O
LC3	B-GP
conversion	O
compared	O
to	O
bafilomycin	O
.	O

Combining	O
data	O
from	O
4	O
and	O
24	O
hour	O
time	O
points	O
suggests	O
a	O
deficit	O
in	O
autophagic	O
flux	O
in	O
CF	B-DS
macrophages	O
,	O
with	O
enhancement	O
through	O
autophagy	O
stimulators	O
such	O
as	O
IFN	B-GP
-	I-GP
γ	I-GP
that	O
are	O
increasing	O
autophagosome	O
formation	O
.	O

Autophagic	O
flux	O
is	O
decreased	O
in	O
CF	B-DS
.	O

3A	O
)	O
Representative	O
immunoblot	O
of	O
4	O
hour	O
treatment	O
protein	O
lysates	O
for	O
LC3	B-GP
-	I-GP
1	I-GP
and	O
LC3	B-GP
-	I-GP
2	I-GP
from	O
non	O
-	O
CF	B-DS
and	O
CF	B-DS
macrophages	O
,	O
with	O
corresponding	O
summed	O
band	O
densitometries	O
normalized	O
to	O
loading	O
control	O
.	O

All	O
lanes	O
are	O
marked	O
with	O
a	O
“+”	O
if	O
the	O
corresponding	O
treatments	O
were	O
added	O
:	O
B	B-DS
.	I-DS
cenocepacia	I-DS
infection	I-DS
(	O
k56	O
-	O
2	O
),	O
autophagy	O
stimulators	O
(	O
IFN	B-GP
-	I-GP
y	I-GP
,	O
Rapamycin	O
)	O
and	O
autophagy	O
inhibitors	O
(	O
Bafilomycin	O
,	O
3	O
-	O
MA	O
).	O

Inhibitors	O
were	O
added	O
one	O
hour	O
prior	O
to	O
infection	B-DS
.	O

Autophagy	O
stimulators	O
were	O
added	O
one	O
hour	O
after	O
infection	B-DS
for	O
a	O
total	O
of	O
4	O
hours	O
of	O
treatment	O
.	O

Data	O
is	O
representative	O
of	O
3	O
independent	O
experiments	O
.	O

3B	O
)	O
Representative	O
immunoblot	O
of	O
24	O
hour	O
treatment	O
protein	O
lysates	O
for	O
LC3	B-GP
-	I-GP
1	I-GP
and	O
LC3	B-GP
-	I-GP
2	I-GP
from	O
non	O
-	O
CF	B-DS
and	O
CF	B-DS
macrophages	O
with	O
corresponding	O
summed	O
band	O
densitometries	O
normalized	O
to	O
loading	O
control	O
.	O

All	O
lanes	O
are	O
marked	O
with	O
a	O
“+”	O
if	O
the	O
corresponding	O
treatments	O
were	O
added	O
:	O
B	B-DS
.	I-DS
cenocepacia	I-DS
infection	I-DS
(	O
k56	O
-	O
2	O
),	O
autophagy	O
stimulators	O
(	O
IFN	B-GP
-	I-GP
y	I-GP
,	O
Rapamycin	O
)	O
and	O
autophagy	O
inhibitors	O
(	O
Bafilomycin	O
,	O
3	O
-	O
MA	O
).	O

Inhibitors	O
were	O
added	O
one	O
hour	O
prior	O
to	O
infection	B-DS
.	O

Autophagy	O
stimulators	O
were	O
added	O
one	O
hour	O
after	O
infection	B-DS
for	O
a	O
total	O
of	O
24	O
hours	O
of	O
treatment	O
.	O

Data	O
is	O
representative	O
of	O
3	O
independent	O
experiments	O
.	O

Autophagy	O
Stimulation	O
Increases	O
Bacterial	O
Clearance	O
in	O
CF	B-DS

B	B-DS
.	I-DS
cenocepacia	I-DS
infection	I-DS
causes	O
increased	O
bacterial	O
burden	O
in	O
human	B-OG
and	O
murine	O
CF	B-DS
cells	O
,	O
indicating	O
an	O
innate	O
defect	O
in	O
clearing	O
the	O
pathogen	O
in	O
CF	B-DS
[	O
19	O
],	O
[	O
22	O
].	O

Persistent	O
bacterial	O
loads	O
can	O
lead	O
to	O
systemic	O
involvement	O
and	O
/	O
or	O
heightened	O
inflammation	O
.	O

Because	O
autophagy	O
regulates	O
pathogen	O
clearance	O
,	O
we	O
stimulated	O
autophagy	O
in	O
MDMs	O
with	O
IFN	B-GP
-	I-GP
y	I-GP
or	O
rapamycin	O
for	O
4	O
and	O
24	O
hours	O
and	O
assessed	O
bacterial	O
clearance	O
by	O
confocal	O
microscopy	O
and	O
CFU	O
.	O

Twenty	O
-	O
four	O
hours	O
is	O
an	O
expected	O
clinical	O
dosing	O
regimen	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
and	O
4	O
hours	O
was	O
chosen	O
to	O
ensure	O
sufficient	O
autophagosome	O
formation	O
,	O
as	O
murine	O
studies	O
have	O
shown	O
that	O
even	O
in	O
wild	O
type	O
macrophages	O
B	B-OG
.	I-OG
cenocepacia	I-OG
requires	O
at	O
least	O
2	O
hours	O
to	O
traffic	O
to	O
autophagosomes	O
.	O

There	O
is	O
no	O
difference	O
in	O
bacterial	O
counts	O
at	O
2	O
hours	O
(	O
figure	O
S2	O
).	O

At	O
4	O
hours	O
of	O
treatment	O
,	O
there	O
were	O
significantly	O
higher	O
bacterial	O
counts	O
in	O
both	O
autophagy	O
-	O
stimulated	O
and	O
unstimulated	O
CF	B-DS
macrophages	O
compared	O
to	O
non	O
-	O
CF	B-DS
macrophages	O
(	O
Figures	O
4A	O
).	O

However	O
,	O
CF	B-DS
macrophages	O
treated	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
for	O
4	O
hours	O
had	O
a	O
higher	O
proportion	O
of	O
bacterial	O
co	O
-	O
localized	O
with	O
autophagosomes	O
as	O
marked	O
by	O
LC3	B-GP
compared	O
to	O
untreated	O
CF	B-DS
macrophages	O
(	O
Figure	O
4A	O
).	O

A	O
24	O
hour	O
treatment	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
or	O
rapamycin	O
markedly	O
reduced	O
bacterial	O
counts	O
in	O
the	O
CF	B-DS
macrophages	O
compared	O
to	O
untreated	O
CF	B-DS
macrophages	O
(	O
Figures	O
4B	O
,	O
4C	O
,	O
4E	O
).	O

These	O
reductions	O
mirror	O
bacterial	O
levels	O
in	O
non	O
-	O
CF	B-DS
macrophages	O
.	O

There	O
was	O
no	O
difference	O
in	O
bacterial	O
counts	O
between	O
CF	B-DS
patients	O
on	O
azithromycin	O
therapy	O
and	O
those	O
not	O
(	O
Supplemental	O
Figure	O
1B	O
).	O

24	O
hour	O
extracellular	O
bacterial	O
counts	O
were	O
not	O
reduced	O
(	O
Figure	O
S2	O
).	O

There	O
is	O
a	O
sustained	O
increase	O
in	O
the	O
co	O
-	O
localization	O
of	O
bacteria	B-OG
with	O
LC3	B-GP
after	O
24	O
hours	O
of	O
autophagy	O
stimulation	O
in	O
CF	B-DS
macrophages	O
compared	O
to	O
untreated	O
CF	B-DS
macrophages	O
(	O
p	O
=	O
0	O
.	O
02	O
,	O
Figures	O
4B	O
,	O
4D	O
).	O

Electron	O
microscopy	O
confirmed	O
these	O
confocal	O
findings	O
.	O

Untreated	O
non	O
-	O
CF	B-DS
macrophages	O
contained	O
double	O
membrane	O
vacuoles	O
surrounding	O
B	B-OG
.	I-OG
cenocepacia	I-OG
,	O
indicative	O
of	O
autophagosome	O
formation	O
(	O
Figure	O
5A	O
).	O

Untreated	O
CF	B-DS
macrophages	O
displayed	O
only	O
single	O
membrane	O
bound	O
vacuoles	O
(	O
5C	O
),	O
but	O
when	O
stimulated	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
CF	B-DS
macrophages	O
displayed	O
double	O
membrane	O
vacuoles	O
similar	O
to	O
the	O
non	O
-	O
CF	B-DS
(	O
5D	O
).	O

This	O
observation	O
suggests	O
autophagosome	O
formation	O
is	O
stimulated	O
upon	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
in	O
the	O
CF	B-DS
MDMs	O
.	O

Additionally	O
,	O
IFN	B-GP
-	I-GP
γ	I-GP
had	O
no	O
direct	O
effects	O
on	O
bacterial	O
growth	O
when	O
added	O
to	O
bacteria	B-OG
in	O
media	O
devoid	O
of	O
MDMs	O
,	O
with	O
no	O
difference	O
in	O
bacterial	O
growth	O
over	O
24	O
hours	O
between	O
media	O
with	O
k56	O
-	O
2	O
alone	O
,	O
and	O
media	O
with	O
k56	O
-	O
2	O
plus	O
IFN	B-GP
-	I-GP
γ	I-GP
(	O
Figure	O
S3	O
).	O

In	O
summation	O
,	O
these	O
results	O
indicate	O
that	O
IFN	B-GP
-	I-GP
γ	I-GP
effectively	O
stimulates	O
early	O
autophagic	O
targeting	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
to	O
autophagosomes	O
,	O
thus	O
allowing	O
enhanced	O
clearance	O
after	O
24	O
hours	O
.	O

IFN	B-GP
-	I-GP
γ	I-GP
increases	O
autophagosome	O
formation	O
.	O

4A	O
)	O
Confocal	O
microscopy	O
for	O
non	O
-	O
CF	B-DS
and	O
CF	B-DS
macrophages	O
infected	O
with	O
m	O
-	O
RFP	B-GP
expressing	O
k56	O
-	O
2	O
.	O

IFN	B-GP
-	I-GP
y	I-GP
treatment	O
was	O
administered	O
after	O
1	O
hour	O
of	O
infection	B-DS
for	O
a	O
4	O
hour	O
treatment	O
period	O
.	O

LC3	B-GP
is	O
stained	O
green	O
,	O
and	O
macrophage	O
nuclei	O
are	O
stained	O
blue	O
with	O
DAPI	O
.	O

Co	O
-	O
localization	O
of	O
bacteria	B-OG
with	O
LC3	B-GP
is	O
noted	O
in	O
yellow	O
in	O
the	O
bottom	O
panel	O
as	O
noted	O
by	O
white	O
arrows	O
.	O

4B	O
)	O
24	O
hour	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
rapamycin	O
treatments	O
similar	O
to	O
4A	O
.	O

4C	O
)	O
Summary	O
of	O
scored	O
bacteria	B-OG
per	O
100	O
macrophages	O
from	O
individual	O
subjects	O
for	O
the	O
confocal	O
microscopy	O
experiments	O
from	O
4B	O
,	O
n	O
=	O
17	O
subjects	O
,	O
with	O
2	O
replicates	O
per	O
subject	O
,	O
unpaired	O
t	O
-	O
test	O
.	O

4D	O
)	O
The	O
percentage	O
of	O
bacterial	O
co	O
-	O
localization	O
with	O
LC3	B-GP
was	O
scored	O
for	O
over	O
100	O
macrophages	O
per	O
condition	O
from	O
4B	O
,	O
n	O
=	O
17	O
subjects	O
,	O
with	O
2	O
replicates	O
per	O
subject	O
,	O
unpaired	O
t	O
-	O
test	O
.	O

4E	O
)	O
CFU	O
counts	O
for	O
non	O
-	O
CF	B-DS
and	O
CF	B-DS
macrophages	O
infected	O
with	O
MHK1	O
for	O
24	O
hours	O
(	O
n	O
=	O
6	O
).	O

IFN	B-GP
-	I-GP
γ	I-GP
stimulates	O
double	O
-	O
membrane	O
autophagosome	O
formation	O
.	O

5A	O
)	O
Electron	O
microscopy	O
of	O
non	O
-	O
CF	B-DS
macrophage	O
infected	O
with	O
k56	O
-	O
2	O
only	O
for	O
24	O
hours	O
.	O

White	O
arrow	O
indicates	O
double	O
membrane	O
formation	O
indicative	O
of	O
autophagosomes	O
.	O

5B	O
)	O
EM	O
of	O
non	O
-	O
CF	B-DS
macrophage	O
treated	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
for	O
24	O
hours	O
.	O

5C	O
)	O
EM	O
of	O
CF	B-DS
macrophage	O
infected	O
with	O
k56	O
-	O
2	O
only	O
.	O

Black	O
arrow	O
indicates	O
single	O
membrane	O
vacuole	O
.	O

5D	O
)	O
EM	O
of	O
CF	B-DS
macrophage	O
treated	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
for	O
24	O
hours	O
.	O

White	O
arrow	O
indicates	O
double	O
membrane	O
formation	O
.	O

Pictures	O
are	O
marked	O
with	O
500	O
nm	O
marker	O
.	O

Lysosome	O
Targeting	O
is	O
Increased	O
in	O
Autophagy	O
Stimulated	O
CF	B-DS
MDMs	O

Rapamycin	O
increases	O
lysosomal	O
degradation	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
CF	B-DS
murine	O
macrophages	O
by	O
promoting	O
phagosome	O
-	O
lysosome	O
fusion	O
via	O
autophagy	O
[	O
22	O
].	O

Human	B-OG
CF	B-DS
macrophages	O
also	O
demonstrate	O
decreased	O
co	O
-	O
localization	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
with	O
lysosomes	O
[	O
19	O
].	O

We	O
examined	O
the	O
extent	O
to	O
which	O
IFN	B-GP
-	I-GP
γ	I-GP
enhances	O
autophagosome	O
fusion	O
with	O
lysosomes	O
by	O
infecting	O
human	B-OG
MDMs	O
with	O
B	B-OG
.	I-OG
cenocepacia	I-OG
for	O
1	O
hour	O
and	O
then	O
treating	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
for	O
2	O
and	O
24	O
hours	O
.	O

We	O
then	O
scored	O
co	O
-	O
localization	O
of	O
a	O
fluorescent	O
lysotracker	O
with	O
bacteria	B-OG
using	O
confocal	O
microscopy	O
.	O

After	O
2	O
hours	O
of	O
infection	B-DS
,	O
untreated	O
CF	B-DS
macrophages	O
exhibited	O
very	O
little	O
co	O
-	O
localization	O
of	O
bacteria	B-OG
with	O
lysosomes	O
(	O
11	O
.	O
5	O
±	O
3	O
.	O
2	O
%,	O
Figures	O
6A	O
,	O
B	O
)	O
compared	O
to	O
non	O
-	O
CF	B-DS
macrophages	O
(	O
29	O
.	O
9	O
±	O
8	O
.	O
5	O
%,	O
Figures	O
6A	O
,	O
B	O
).	O

However	O
,	O
CF	B-DS
macrophages	O
treated	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
demonstrate	O
increased	O
lysosomal	O
co	O
-	O
localization	O
of	O
bacteria	B-OG
(	O
26	O
.	O
5	O
±.	O
5	O
%,	O
p	O
<	O
0	O
.	O
0001	O
,	O
Figures	O
6A	O
,	O
B	O
).	O

After	O
24	O
hours	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
therapy	O
CF	B-DS
macrophages	O
demonstrated	O
a	O
sustained	O
lysosomal	O
co	O
-	O
localization	O
of	O
remaining	O
bacteria	B-OG
,	O
similar	O
to	O
what	O
was	O
observed	O
in	O
non	O
-	O
CF	B-DS
macrophages	O
(	O
34	O
.	O
8	O
±	O
5	O
.	O
4	O
%	O
vs	O
.	O
37	O
.	O
0	O
±	O
9	O
.	O
5	O
%,	O
p	O
=	O
0	O
.	O
5	O
,	O
Figures	O
6C	O
,	O
D	O
).	O

Untreated	O
CF	B-DS
macrophages	O
have	O
significantly	O
less	O
lysosomal	O
co	O
-	O
localization	O
compared	O
to	O
treated	O
CF	B-DS
macrophages	O
at	O
24	O
hours	O
.	O

(	O
25	O
.	O
1	O
±	O
9	O
.	O
4	O
%,	O
p	O
=	O
0	O
.	O
038	O
,	O
Figures	O
6C	O
,	O
D	O
).	O

Together	O
,	O
the	O
results	O
demonstrate	O
delayed	O
lysosomal	O
targeting	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
CF	B-DS
MDMs	O
.	O

Combined	O
with	O
prior	O
results	O
,	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
increases	O
autophagosome	O
formation	O
in	O
CF	B-DS
macrophages	O
,	O
enhancing	O
lysosomal	O
targeting	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
.	O

Lysosomal	O
co	O
-	O
localization	O
is	O
increased	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
in	O
CF	B-DS
.	O

6A	O
)	O
Confocal	O
microscopy	O
for	O
non	O
-	O
CF	B-DS
and	O
CF	B-DS
macrophages	O
infected	O
with	O
k56	O
-	O
2	O
.	O

Macrophages	O
were	O
labeled	O
with	O
green	O
lysotracker	O
and	O
bacterial	O
co	O
-	O
localization	O
to	O
lysosomes	O
was	O
measured	O
after	O
a	O
2	O
hour	O
infection	B-DS
.	O

Macrophage	O
nuclei	O
are	O
stained	O
blue	O
with	O
DAPI	O
.	O

Co	O
-	O
localization	O
of	O
bacteria	B-OG
with	O
lysotracker	O
is	O
noted	O
in	O
yellow	O
by	O
white	O
arrows	O
.	O

6B	O
)	O
Quantitative	O
scoring	O
of	O
%	O
bacterial	O
co	O
-	O
localization	O
with	O
lysosomes	O
from	O
6A	O
,	O
n	O
=	O
8	O
subjects	O
,	O
Mann	O
-	O
Whitney	O
testing	O
.	O

6C	O
)	O
24	O
hour	O
k56	O
-	O
2	O
infection	B-DS
with	O
lysotracker	O
staining	O
.	O

6D	O
)	O
Bacterial	O
co	O
-	O
localization	O
with	O
lysotracker	O
quantitative	O
scoring	O
for	O
5C	O
,	O
n	O
=	O
8	O
subjects	O
,	O
Mann	O
-	O
Whitney	O
testing	O
.	O

IL	B-GP
-	I-GP
1β	I-GP
Production	O
is	O
Decreased	O
with	O
Autophagy	O
Stimulation	O

CF	B-DS
macrophages	O
excessively	O
produce	O
the	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
IL	B-GP
-	I-GP
1β	I-GP
in	O
response	O
to	O
B	B-DS
.	I-DS
cenocepacia	I-DS
infection	I-DS
[	O
19	O
],	O
[	O
50	O
].	O

Human	B-OG
bronchial	O
epithelial	O
cells	O
do	O
not	O
produce	O
IL	B-GP
-	I-GP
1β	I-GP
in	O
response	O
to	O
B	B-OG
.	I-OG
cenocepacia	I-OG
[	O
51	O
].	O

During	O
B	B-DS
.	I-DS
cenocepacia	I-DS
infection	I-DS
pyrin	B-GP
inflammasome	B-GP
activation	O
results	O
in	O
IL	B-GP
-	I-GP
1β	I-GP
release	O
from	O
mononuclear	O
cells	O
[	O
52	O
].	O

Therefore	O
,	O
we	O
measured	O
IL	B-GP
-	I-GP
1β	I-GP
production	O
in	O
human	B-OG
CF	B-DS
macrophages	O
after	O
autophagy	O
stimulation	O
as	O
a	O
primary	O
source	O
of	O
excess	O
inflammatory	B-GP
cytokine	I-GP
production	O
during	O
infection	B-DS
.	O

MDMs	O
were	O
infected	O
with	O
B	B-OG
.	I-OG
cenocepacia	I-OG
and	O
treated	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
or	O
rapamycin	O
for	O
4	O
and	O
24	O
hours	O
and	O
cell	O
supernatants	O
were	O
examined	O
by	O
ELISA	O
for	O
IL	B-GP
-	I-GP
1β	I-GP
production	O
.	O

After	O
4	O
hours	O
of	O
autophagy	O
stimulation	O
,	O
IL	B-GP
-	I-GP
1β	I-GP
levels	O
were	O
similar	O
between	O
treated	O
and	O
untreated	O
CF	B-DS
macrophages	O
,	O
but	O
CF	B-DS
macrophages	O
had	O
significantly	O
more	O
IL	B-GP
-	I-GP
1β	I-GP
than	O
non	O
-	O
CF	B-DS
macrophages	O
(	O
p	O
=	O
0	O
.	O
0012	O
,	O
Figure	O
7A	O
).	O

However	O
,	O
in	O
CF	B-DS
macrophages	O
treated	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
IL	B-GP
-	I-GP
1β	I-GP
levels	O
diminished	O
by	O
24	O
hours	O
of	O
treatment	O
(	O
p	O
=	O
0	O
.	O
045	O
),	O
while	O
untreated	O
CF	B-DS
macrophages	O
infected	O
with	O
B	B-OG
.	I-OG
cenocepacia	I-OG
perpetuate	O
elevated	O
IL	B-GP
-	I-GP
1β	I-GP
production	O
(	O
Figure	O
7B	O
).	O

There	O
was	O
no	O
difference	O
in	O
IL	B-GP
-	I-GP
1β	I-GP
production	O
between	O
CF	B-DS
patients	O
on	O
azithromycin	O
therapy	O
and	O
those	O
not	O
(	O
figure	O
S1C	O
).	O

IL	B-GP
-	I-GP
10	I-GP
was	O
also	O
measured	O
as	O
it	O
can	O
directly	O
impair	O
IFN	B-GP
-	I-GP
γ	I-GP
signaling	O
pathways	O
and	O
its	O
production	O
can	O
correlate	O
with	O
inflammatory	B-GP
cytokines	I-GP
such	O
as	O
IL	B-GP
-	I-GP
1β	I-GP
.	O

There	O
was	O
no	O
difference	O
in	O
IL	B-GP
-	I-GP
10	I-GP
production	O
in	O
24	O
hour	O
supernatants	O
between	O
uninfected	O
,	O
infected	O
,	O
and	O
IFN	B-GP
-	I-GP
γ	I-GP
treated	O
CF	B-DS
and	O
non	O
-	O
CF	B-DS
macrophages	O
(	O
Figure	O
7C	O
).	O

These	O
results	O
demonstrate	O
autophagy	O
induction	O
plays	O
a	O
role	O
in	O
reducing	O
IL	B-GP
-	I-GP
1β	I-GP
production	O
in	O
macrophage	O
responses	O
to	O
B	B-OG
.	I-OG
cenocepacia	I-OG
.	O

IL	B-GP
-	I-GP
1β	I-GP
is	O
decreased	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
in	O
CF	B-DS
.	O

IL	B-GP
-	I-GP
1β	I-GP
levels	O
in	O
macrophage	O
supernatants	O
after	O
infection	B-DS
with	O
k56	O
-	O
2	O
and	O
either	O
a	O
4	O
hour	O
treatment	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
or	O
a	O
control	O
diluent	O
(	O
7A	O
)	O
or	O
a	O
24	O
hour	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
(	O
7B	O
),	O
n	O
=	O
7	O
subjects	O
,	O
Mann	O
-	O
Whitney	O
analysis	O
.	O

7C	O
)	O
IL	B-GP
-	I-GP
10	I-GP
levels	O
in	O
macrophage	O
supernatants	O
after	O
infection	B-DS
with	O
k56	O
-	O
2	O
and	O
a	O
24	O
hour	O
treatment	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
or	O
a	O
control	O
diluent	O
,	O
n	O
=	O
7	O
subjects	O
,	O
Mann	O
-	O
Whitney	O
analysis	O
.	O

Significant	O
differences	O
are	O
noted	O
.	O

Cell	O
Death	O
is	O
Decreased	O
by	O
IFN	B-GP
-	I-GP
γ	I-GP
Treatment	O
during	O
B	B-DS
.	I-DS
cenocepacia	I-DS
Infection	I-DS

B	B-OG
.	I-OG
cenocepacia	I-OG
promotes	O
increased	O
cell	O
death	O
in	O
human	B-OG
CF	B-DS
macrophages	O
[	O
19	O
].	O

Autophagy	O
has	O
an	O
interconnected	O
role	O
with	O
apoptosis	O
and	O
necrosis	O
in	O
the	O
regulation	O
of	O
cell	O
death	O
[	O
53	O
].	O

We	O
examined	O
MDMs	O
for	O
LDH	B-GP
release	O
at	O
4	O
and	O
24	O
hours	O
after	O
infection	B-DS
to	O
assess	O
cell	O
death	O
as	O
a	O
result	O
of	O
autophagy	O
stimulation	O
in	O
CF	B-DS
macrophages	O
infected	O
with	O
B	B-OG
.	I-OG
cenocepacia	I-OG
.	O

After	O
4	O
hours	O
of	O
infection	B-DS
IFN	B-GP
-	I-GP
γ	I-GP
treated	O
CF	B-DS
MDMs	O
trended	O
towards	O
higher	O
cell	O
death	O
compared	O
to	O
untreated	O
CF	B-DS
MDMs	O
(	O
Figure	O
8A	O
).	O

All	O
CF	B-DS
macrophages	O
had	O
higher	O
cell	O
death	O
than	O
non	O
-	O
CF	B-DS
macrophages	O
(	O
Figure	O
8A	O
).	O

After	O
24	O
of	O
infection	B-DS
CF	B-DS
macrophages	O
remained	O
with	O
slightly	O
higher	O
cell	O
death	O
than	O
non	O
-	O
CF	B-DS
,	O
except	O
for	O
IFN	B-GP
-	I-GP
γ	I-GP
treated	O
CF	B-DS
MDMs	O
.	O

There	O
was	O
also	O
no	O
difference	O
among	O
autophagy	O
stimulated	O
CF	B-DS
macrophages	O
compared	O
to	O
un	O
-	O
stimulated	O
CF	B-DS
macrophages	O
(	O
Figures	O
8B	O
).	O

Macrophage	O
viability	O
was	O
additionally	O
assessed	O
at	O
24	O
hours	O
of	O
infection	B-DS
via	O
a	O
naphthol	O
blue	O
/	O
black	O
assay	O
.	O

At	O
24	O
hours	O
there	O
was	O
no	O
difference	O
in	O
macrophage	O
viability	O
between	O
CF	B-DS
and	O
non	O
CF	B-DS
macrophage	O
(	O
Figure	O
8C	O
).	O

Macrophage	O
viability	O
was	O
not	O
decreased	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
(	O
Figure	O
8c	O
).	O

Taken	O
together	O
,	O
this	O
data	O
suggests	O
that	O
autophagic	O
clearance	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
CF	B-DS
macrophages	O
decreases	O
cell	O
death	O
in	O
a	O
human	B-OG
model	O
after	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
.	O

Cell	O
death	O
is	O
decreased	O
with	O
autophagy	O
stimulation	O
in	O
CF	B-DS
.	O

Percent	O
LDH	B-GP
release	O
from	O
MDM	O
supernatants	O
treated	O
with	O
autophagy	O
stimulators	O
IFN	B-GP
-	I-GP
γ	I-GP
or	O
Rapamycin	O
for	O
4	O
hours	O
(	O
8A	O
)	O
or	O
24	O
hours	O
(	O
8B	O
),	O
n	O
=	O
at	O
least	O
6	O
subjects	O
per	O
condition	O
,	O
Mann	O
-	O
Whitney	O
testing	O
.	O

8c	O
)	O
Percent	O
of	O
macrophages	O
deemed	O
viable	O
per	O
naphthol	O
staining	O
after	O
a	O
24	O
hour	O
infection	B-DS
,	O
n	O
=	O
2	O
.	O

Discussion	O

The	O
discovery	O
of	O
new	O
therapeutic	O
classes	O
or	O
novel	O
utilization	O
of	O
existing	O
therapeutics	O
is	O
imperative	O
for	O
CF	B-DS
patients	O
infected	O
with	O
B	B-OG
.	I-OG
cenocepacia	I-OG
due	O
to	O
its	O
devastating	O
impact	O
on	O
morbidity	O
and	O
mortality	O
.	O

Here	O
,	O
we	O
demonstrate	O
the	O
effectiveness	O
of	O
autophagy	O
stimulation	O
as	O
a	O
therapeutic	O
class	O
,	O
specifically	O
IFN	B-GP
-	I-GP
γ	I-GP
in	O
clearing	O
B	B-OG
.	I-OG
cenocepacia	I-OG
from	O
human	B-OG
CF	B-DS
macrophages	O
.	O

This	O
is	O
a	O
crucial	O
finding	O
considering	O
the	O
mounting	O
evidence	O
for	O
CFTR	B-GP
dysfunction	O
in	O
monocyte	O
-	O
pathogen	O
interactions	O
in	O
CF	B-DS
[	O
54	O
],	O
as	O
well	O
as	O
the	O
ability	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
to	O
replicate	O
within	O
macrophages	O
[	O
24	O
],	O
[	O
55	O
].	O

By	O
improving	O
the	O
clearance	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
from	O
macrophages	O
,	O
we	O
can	O
minimize	O
the	O
chances	O
of	O
overwhelming	O
bacteremia	B-DS
as	O
well	O
as	O
reduce	O
continued	O
pro	O
-	O
inflammatory	O
signaling	O
.	O

Our	O
work	O
is	O
aligned	O
well	O
with	O
a	O
recent	O
study	O
from	O
Al	O
-	O
Khodor	O
and	O
colleagues	O
in	O
CGD	B-DS
macrophages	O
[	O
38	O
],	O
and	O
importantly	O
demonstrates	O
the	O
effectiveness	O
of	O
a	O
post	O
infection	B-DS
therapeutic	O
intervention	O
.	O

Autophagy	O
stimulation	O
also	O
holds	O
the	O
promise	O
of	O
clearing	O
other	O
pathogens	O
in	O
CF	B-DS
besides	O
B	B-OG
.	I-OG
cenocepacia	I-OG
[	O
27	O
],	O
[	O
28	O
],	O
[	O
56	O
],	O
as	O
well	O
as	O
facilitating	O
CFTR	B-GP
trafficking	O
[	O
30	O
].	O

IFN	B-GP
-	I-GP
γ	I-GP
has	O
numerous	O
signaling	O
effects	O
in	O
the	O
body	O
including	O
host	O
defense	O
,	O
autoimmunity	O
,	O
inflammatory	O
responses	O
,	O
and	O
is	O
a	O
major	O
activator	O
of	O
macrophages	O
[	O
57	O
].	O

Importantly	O
,	O
we	O
found	O
deficient	O
production	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
with	O
adequate	O
receptor	O
expression	O
in	O
CF	B-DS
PBMCs	O
in	O
response	O
to	O
B	B-OG
.	I-OG
cenocepacia	I-OG
compared	O
to	O
non	O
-	O
CF	B-DS
PBMCs	O
,	O
suggesting	O
a	O
natural	O
defect	O
in	O
CF	B-DS
macrophage	O
priming	O
/	O
pathogen	O
response	O
.	O

This	O
was	O
in	O
contrast	O
to	O
our	O
previous	O
work	O
with	O
the	O
J2315	O
strain	O
[	O
19	O
],	O
however	O
our	O
previous	O
study	O
may	O
have	O
been	O
affected	O
by	O
the	O
different	O
strain	O
as	O
well	O
as	O
negligible	O
baseline	O
IFN	B-GP
-	I-GP
γ	I-GP
from	O
pure	O
macrophage	O
cultures	O
.	O

IFN	B-GP
-	I-GP
γ	I-GP
has	O
been	O
previously	O
studied	O
in	O
CF	B-DS
as	O
an	O
inhalational	O
therapy	O
in	O
patients	O
without	O
Burkholderia	B-DS
infections	I-DS
,	O
demonstrating	O
no	O
significant	O
effects	O
on	O
lung	O
function	O
,	O
sputum	O
bacterial	O
density	O
,	O
or	O
inflammatory	O
sputum	O
markers	O
[	O
41	O
].	O

However	O
,	O
in	O
that	O
study	O
only	O
2	O
of	O
the	O
48	O
treated	O
patients	O
had	O
detected	O
serum	O
IFN	B-GP
-	I-GP
γ	I-GP
levels	O
,	O
and	O
they	O
did	O
not	O
measure	O
lower	O
airway	O
IFN	B-GP
-	I-GP
γ	I-GP
levels	O
to	O
monitor	O
deposition	O
efficacy	O
.	O

Furthermore	O
,	O
the	O
effective	O
aerosol	O
deposition	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
is	O
low	O
in	O
several	O
non	O
-	O
CF	B-DS
studies	O
,	O
which	O
questions	O
the	O
efficacy	O
of	O
the	O
aforementioned	O
CF	B-DS
study	O
as	O
alveolar	O
macrophages	O
would	O
not	O
be	O
affected	O
by	O
upper	O
airway	O
deposition	O
.	O

A	O
2004	O
study	O
of	O
aerosolized	O
IFN	B-GP
-	I-GP
γ	I-GP
in	O
TB	B-DS
patients	O
demonstrated	O
greater	O
upper	O
airway	O
deposition	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
than	O
lower	O
airway	O
,	O
with	O
a	O
mean	O
lower	O
airway	O
deposition	O
of	O
only	O
35	O
.	O
8	O
µg	O
of	O
a	O
500	O
ug	O
dose	O
[	O
58	O
].	O

Recent	O
studies	O
in	O
patients	O
with	O
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
demonstrated	O
only	O
65	O
%	O
lower	O
airway	O
deposition	O
using	O
a	O
Philips	O
Respironics	O
I	O
-	O
neb	O
[	O
59	O
].	O

Based	O
on	O
the	O
sputum	O
density	O
of	O
CF	B-DS
patients	O
it	O
is	O
reasonable	O
to	O
assume	O
that	O
nebulized	O
concentrations	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
would	O
be	O
even	O
lower	O
in	O
CF	B-DS
patients	O
’	O
lower	O
airways	O
,	O
necessitating	O
systemic	O
IFN	B-GP
-	I-GP
γ	I-GP
use	O
in	O
situations	O
such	O
as	O
B	B-DS
.	I-DS
cenocepacia	I-DS
septicemia	I-DS
or	O
worsening	O
patient	O
progression	O
until	O
improved	O
aerosol	O
deposition	O
can	O
be	O
achieved	O
.	O

Prior	O
studies	O
in	O
CF	B-DS
murine	O
models	O
of	O
P	B-DS
.	I-DS
aeruginosa	I-DS
infection	I-DS
effectively	O
utilized	O
IFN	B-GP
-	I-GP
γ	I-GP
as	O
a	O
systemic	O
therapy	O
[	O
60	O
],	O
and	O
patients	O
with	O
CGD	B-DS
inject	O
IFN	B-GP
-	I-GP
γ	I-GP
subcutaneously	O
to	O
prevent	O
infections	B-DS
with	O
species	O
including	O
Burkholderia	B-OG
[	O
34	O
].	O

Known	O
side	O
effects	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
administration	O
are	O
fever	O
,	O
headaches	O
,	O
myalgias	O
,	O
fatigue	O
,	O
irritability	O
,	O
and	O
flulike	B-DS
syndromes	I-DS
,	O
but	O
overall	O
it	O
has	O
been	O
safely	O
used	O
in	O
CGD	B-DS
[	O
61	O
].	O

The	O
effects	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
on	O
the	O
total	O
CF	B-DS
microbiome	O
still	O
remain	O
to	O
be	O
characterized	O
,	O
but	O
on	O
individual	O
pathogens	O
such	O
as	O
B	B-OG
.	I-OG
cenocepacia	I-OG
and	O
P	B-OG
.	I-OG
aeruginosa	I-OG
,	O
there	O
is	O
a	O
demonstrable	O
benefit	O
on	O
bacterial	O
clearance	O
.	O

Autophagy	O
stimulation	O
is	O
also	O
known	O
to	O
reduce	O
inflammasome	B-GP
mediated	O
IL	B-GP
-	I-GP
1β	I-GP
production	O
[	O
62	O
]	O
and	O
attenuates	O
hyperinflammatory	O
responses	O
from	O
CF	B-DS
cells	O
[	O
29	O
]	O
independent	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
.	O
We	O
demonstrated	O
that	O
IFN	B-GP
-	I-GP
γ	I-GP
was	O
effective	O
in	O
reducing	O
the	O
exaggerated	O
IL	B-GP
-	I-GP
1β	I-GP
production	O
that	O
is	O
observed	O
in	O
response	O
to	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
CF	B-DS
macrophages	O
.	O

This	O
result	O
was	O
not	O
unexpected	O
given	O
the	O
possibility	O
of	O
inflammasome	B-GP
dependent	O
IFN	B-GP
-	I-GP
γ	I-GP
signaling	O
[	O
63	O
],	O
as	O
well	O
as	O
the	O
observed	O
reduction	O
in	O
bacteria	B-OG
with	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
in	O
the	O
CF	B-DS
macrophages	O
.	O

Therefore	O
,	O
our	O
results	O
suggest	O
the	O
reductions	O
in	O
IL	B-GP
-	I-GP
1β	I-GP
are	O
likely	O
due	O
to	O
both	O
the	O
reduced	O
burden	O
observed	O
and	O
dampened	O
inflammasome	B-GP
activation	O
.	O

IL	B-GP
-	I-GP
10	I-GP
was	O
unchanged	O
with	O
treatment	O
,	O
but	O
was	O
not	O
significantly	O
different	O
between	O
CF	B-DS
and	O
non	O
CF	B-DS
prior	O
to	O
treatment	O
,	O
and	O
therefore	O
not	O
likely	O
to	O
be	O
reduced	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
therapy	O
.	O

Importantly	O
,	O
IL	B-GP
-	I-GP
10	I-GP
was	O
not	O
significantly	O
overproduced	O
in	O
response	O
to	O
therapy	O
.	O

In	O
addition	O
to	O
reductions	O
in	O
bacteria	B-OG
and	O
inflammatory	B-GP
cytokines	I-GP
,	O
autophagy	O
stimulation	O
was	O
effective	O
in	O
increasing	O
autophagosome	O
formation	O
and	O
trafficking	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
to	O
lysosomes	O
.	O
B	B-OG
.	I-OG
cenocepacia	I-OG
-	O
containing	O
vacuoles	O
have	O
been	O
shown	O
to	O
have	O
prolonged	O
arrest	O
phases	O
[	O
64	O
],	O
and	O
the	O
ability	O
to	O
correctly	O
utilize	O
otherwise	O
sequestered	O
autophagic	O
machinery	O
may	O
be	O
key	O
in	O
overcoming	O
this	O
delay	O
.	O

Electron	O
microscopy	O
confirmed	O
the	O
presence	O
of	O
single	O
membrane	O
vacuoles	O
containing	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
untreated	O
CF	B-DS
macrophages	O
that	O
were	O
effectively	O
converted	O
to	O
double	O
membrane	O
autophagosomes	O
upon	O
IFN	B-GP
-	I-GP
γ	I-GP
stimulation	O
.	O

This	O
process	O
was	O
marked	O
by	O
decreased	O
p62	B-GP
accumulation	O
and	O
decreased	O
LC3	B-GP
-	I-GP
I	I-GP
accumulation	O
,	O
suggesting	O
effective	O
autophagic	O
flux	O
,	O
allowing	O
for	O
early	O
autophagolysosomal	O
fusion	O
and	O
subsequent	O
bacterial	O
clearance	O
.	O

This	O
study	O
is	O
limited	O
by	O
the	O
use	O
of	O
a	O
single	O
pathogen	O
model	O
,	O
which	O
was	O
necessary	O
to	O
accurately	O
follow	O
B	B-OG
.	I-OG
cenocepacia	I-OG
trafficking	O
as	O
well	O
as	O
cytokine	B-GP
production	O
.	O

Future	O
studies	O
will	O
examine	O
multi	O
-	O
pathogen	O
models	O
to	O
examine	O
more	O
closely	O
effects	O
on	O
pathogen	O
interactions	O
.	O

Further	O
work	O
is	O
also	O
needed	O
in	O
vivo	O
to	O
determine	O
the	O
benefits	O
in	O
human	B-OG
subjects	O
.	O
B	B-OG
.	I-OG
cenocepacia	I-OG
also	O
possesses	O
several	O
quorum	O
sensing	O
systems	O
that	O
may	O
affect	O
its	O
activity	O
in	O
humans	B-OG
and	O
during	O
a	O
24	O
hour	O
infection	B-DS
model	O
[	O
65	O
]–[	O
67	O
].	O

This	O
will	O
be	O
important	O
to	O
consider	O
in	O
future	O
multi	O
-	O
pathogen	O
studies	O
.	O

Additionally	O
,	O
we	O
tried	O
to	O
overcome	O
inherent	O
human	B-OG
subject	O
differences	O
in	O
cell	O
signaling	O
and	O
baseline	O
medications	O
through	O
the	O
use	O
of	O
multiple	O
subjects	O
.	O

Importantly	O
,	O
we	O
did	O
not	O
see	O
differences	O
in	O
B	B-OG
.	I-OG
cenocepacia	I-OG
clearance	O
by	O
CF	B-DS
patients	O
chronically	O
on	O
azithromycin	O
,	O
but	O
samples	O
did	O
not	O
receive	O
further	O
supplementation	O
with	O
azithromycin	O
during	O
any	O
of	O
the	O
experiments	O
.	O

In	O
summary	O
,	O
CF	B-DS
macrophages	O
have	O
a	O
deficient	O
IFN	B-GP
-	I-GP
γ	I-GP
response	O
to	O
B	B-OG
.	I-OG
cenocepacia	I-OG
,	O
ineffective	O
utilization	O
of	O
the	O
autophagy	O
cargo	O
molecule	O
p62	B-GP
,	O
decreased	O
autophagosome	O
formation	O
,	O
and	O
delayed	O
lysosomal	O
uptake	O
.	O

IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
increased	O
autophagy	O
mediated	O
clearance	O
of	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
human	B-OG
CF	B-DS
macrophages	O
via	O
increased	O
autophagosome	O
formation	O
and	O
lysosomal	O
trafficking	O
,	O
and	O
was	O
associated	O
with	O
decreased	O
inflammatory	B-GP
cytokine	I-GP
production	O
.	O

The	O
use	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
or	O
autophagy	O
stimulating	O
drugs	O
is	O
promising	O
for	O
treating	O
life	O
-	O
threatening	O
or	O
chronic	B-DS
infections	I-DS
from	O
B	B-OG
.	I-OG
cenocepacia	I-OG
in	O
patients	O
with	O
CF	B-DS
,	O
but	O
further	O
study	O
is	O
needed	O
to	O
determine	O
their	O
efficacy	O
outside	O
of	O
cell	O
culture	O
models	O
.	O

Supporting	O
Information	O

Chronic	O
azithromycin	O
use	O
has	O
no	O
effect	O
on	O
CF	B-DS
MDMs	O
.	O
S1A	O
)	O
Serum	O
(	O
n	O
=	O
7	O
)	O
and	O
infected	O
PBMC	O
(	O
k56	O
,	O
n	O
=	O
5	O
)	O
IFN	B-GP
-	I-GP
γ	I-GP
levels	O
from	O
CF	B-DS
and	O
non	O
-	O
CF	B-DS
patients	O
separated	O
by	O
patients	O
with	O
(+	O
azithromycin	O
)	O
and	O
without	O
chronic	O
azithromycin	O
prophylaxis	O
.	O

S1B	O
)	O
Summary	O
of	O
scored	O
bacteria	B-OG
per	O
100	O
macrophages	O
from	O
individual	O
subjects	O
for	O
the	O
confocal	O
microscopy	O
experiments	O
from	O
4B	O
and	O
separated	O
by	O
patients	O
with	O
(+	O
azithromycin	O
)	O
and	O
without	O
chronic	O
azithromycin	O
prophylaxis	O
.	O

S1C	O
)	O
IL	B-GP
-	I-GP
1β	I-GP
levels	O
in	O
macrophage	O
supernatants	O
after	O
infection	B-DS
with	O
k56	O
-	O
2	O
and	O
either	O
a	O
24	O
hour	O
treatment	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
or	O
a	O
control	O
diluent	O
and	O
separated	O
by	O
patients	O
with	O
(+	O
azithromycin	O
)	O
and	O
without	O
chronic	O
azithromycin	O
prophylaxis	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

No	O
difference	O
in	O
2	O
hour	O
or	O
supernatant	O
CFUs	O
.	O
CFU	O
counts	O
for	O
non	O
-	O
CF	B-DS
and	O
CF	B-DS
macrophages	O
infected	O
with	O
MHK1	O
for	O
2	O
(	O
n	O
=	O
3	O
)	O
and	O
24	O
hour	O
supernatants	O
(	O
n	O
=	O
3	O
)	O
with	O
or	O
without	O
IFN	B-GP
-	I-GP
γ	I-GP
treatment	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

IFN	B-GP
-	I-GP
γ	I-GP
has	O
no	O
effect	O
on	O
bacterial	O
growth	O
in	O
media	O
devoid	O
of	O
MDMs	O
.	O
Optical	O
density	O
(	O
OD	O
)	O
of	O
bacteria	B-OG
cultured	O
in	O
LB	O
broth	O
alone	O
(	O
k56	O
-	O
2	O
)	O
versus	O
LB	O
+	O
IFN	B-GP
-	I-GP
γ	I-GP
(	O
IFN	B-GP
-	I-GP
γ	I-GP
)	O
was	O
compared	O
over	O
24	O
hours	O
during	O
normal	O
growth	O
conditions	O
at	O
37	O
°	O
with	O
high	O
amplitude	O
shaking	O
.	O

Inset	O
shows	O
negligible	O
difference	O
at	O
24	O
hours	O
in	O
OD	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

